Talking Ketamine Podcast Podcast Por Talking Ketamine arte de portada

Talking Ketamine Podcast

Talking Ketamine Podcast

De: Talking Ketamine
Escúchala gratis

Explore the cutting-edge science and therapeutic potential of ketamine. Talking Ketamine offers evidence-based discussions to demystify its role in mental health and beyond, providing informed insights into this powerful compound. RSSVERIFY© 2025 Talking Ketamine Ciencia Ciencias Biológicas Higiene y Vida Saludable Medicina Alternativa y Complementaria Psicología Psicología y Salud Mental
Episodios
  • Ketamine, the Cognitive Enhancer

    Ketamine, the Cognitive Enhancer
    Apr 2 2026
    For decades, neurology has viewed adult brain damage as a relatively permanent state, offering mostly compensatory therapies to help patients adapt to their deficits. But Episode 59 explores a 2026 systematic review by Leon-Rojas and Sacks-Zimmerman that flips the script: could subanesthetic ketamine actually act as a powerful cognitive enhancer? We unpack the paradox of using a dissociative anesthetic to sharpen the mind. The secret lies in looking past the acute intoxication phase—the temporary "construction zone"—to the structural remodeling that follows. We explore ketamine's two-phase neuroprotective mechanism: acting first as a "fire extinguisher" to block NMDA receptors and stop toxic glutamate floods (excitotoxicity), and second as "fertilizer" by releasing BDNF to sprout new neural bridges (synaptogenesis). While animal models show a staggering 93.2% success rate in restoring cognitive functions like working memory and spatial learning, the review's single human study on Huntington's disease showed short-term cognitive impairment. We discuss why timing and context are everything: to truly harness this drug, the biological "window of neuroplasticity" must be actively paired with rigorous, targeted neurorehabilitation to guide the brain's rewiring. Reference: Leon-Rojas, J. E., Mascialino, G., Vinueza Mera, L., Hinojosa-Figueroa, M. S., Navas Arias, C. F., Cadena Barberis, E. D., & Sacks-Zimmerman, A. (2026). Ketamine as a potential cognitive enhancer in neurological disorders: Evidence from preclinical and clinical studies. Frontiers in Neurology, 17, 1786249. https://doi.org/10.3389/fneur.2026.1786249
    Más Menos
    17 m
  • Ketamine and Joy

    Ketamine and Joy
    Mar 26 2026
    For decades, the clinical focus of treating Major Depressive Disorder has been on alleviating profound sadness. However, traditional monoaminergic antidepressants often fall short of treating anhedonia—the absolute absence of pleasure—and can even cause "emotional blunting" by placing an artificial ceiling on a patient's dopamine-driven joy. In Episode 58, we explore a landmark 2026 systematic review by Faisal and colleagues that synthesizes 13 neuroimaging studies to show how ketamine acts not just as an antidepressant, but as a "pro-joy intervention." We break down the brain's reward architecture into the "Engine" (primitive structures like the striatum and nucleus accumbens) and the "Steering Wheel" (the prefrontal cortex). Chronic depression causes the dendritic spines connecting these regions to wither, leaving the engine dead. But the neuroimaging data is staggering: functional MRI (fMRI) measuring the BOLD signal during the Monetary Incentive Delay task shows that ketamine rapidly reactivates the striatum's response to reward anticipation. We also dive into PET scan data, revealing how ketamine modulates the 5-HT1B serotonin receptor—acting like a "bouncer" to remove the brakes from the dopamine system. Ultimately, this episode offers profound vindication for patients stuck in the gray zone: anhedonia is not a moral failing or a psychological attitude, but a physical deficit in the brain's wiring that ketamine is structurally capable of repairing. Reference: Faisal, H., Le, G. H., Kwan, A. T. H., Wong, S., Cheung, W., Dri, C. E., Cao, B., Rhee, T. G., Bargiota, S., Lo, H. K. Y., Shen, B., Guillen-Burgos, H. F., & McIntyre, R. S. (2026). Effect of ketamine on reward processing in depressive disorders: A systematic review of neuroimaging studies. CNS Spectrums. https://doi.org/10.1017/S109285292610087X
    Más Menos
    20 m
  • Ketamine's Brainwave Fingerprint

    Ketamine's Brainwave Fingerprint
    Mar 20 2026
    In Episode 57, we explore a groundbreaking 2026 study out of Hungary by Koncz and colleagues that challenges the foundation of modern psychiatry: do you actually have to "trip" to heal? For years, the pharmaceutical industry has searched for a sanitized, at-home version of ketamine, hoping that R-ketamine (arketamine) could deliver neuroplasticity without the intense psychotomimetic effects of standard S-ketamine (esketamine). By utilizing quantitative EEG (qEEG) signals, researchers discovered the "Gamma-Delta Shift"—the electrical signature of the brain actively rewiring. S-ketamine acts like a controlled forest fire: it triggers a massive, high-frequency "gamma storm" (the trip) which creates a massive cellular energy debt. This debt forces a mandatory "delta rebound" during deep sleep, which is when the actual physical remodeling and synaptic plasticity occur. The shocking twist? Even at four times the normal dose, arketamine completely failed to trigger this shift. This perfectly mirrors its recent failure in human clinical trials, where it did not show a statistically significant antidepressant effect compared to a placebo. The data draws a clear line: you cannot bypass the chaotic exertion phase and still get the structural repair. The altered state isn't a side effect to be engineered away; it is a necessary feature of the cure. Reference: Koncz, S., Pothorszki, D., Papp, N., Pál, D., & Bagdy, G. (2026). Differential effects of ketamine enantiomers on EEG parameters including the gamma-delta shift phenomenon. British Journal of Pharmacology, 1-15. https://doi.org/10.1111/bph.70399
    Más Menos
    17 m
Todavía no hay opiniones